Bladder Cancer

A recently approved antibody-drug conjugate provides another much-needed treatment choice for patients with locally advanced and metastatic urothelial cancer.

Preliminary results of the phase 2 trial assessing the safety and efficacy of Cosela with gemcitabine/platinum-based chemotherapy and Bavencio maintenance therapy for metastatic bladder cancer are expected to be released in the second half of 2022.

The FDA granted approval to Opdivo as an adjuvant treatment in patients with high-risk urothelial carcinoma.

Intravesical therapy for patients with non-muscle invasive bladder cancer was found to have an impact on patients’ social, emotional and physical health.

Smoking cigarettes could lead to a four-fold increased risk of recurrence in patients with a previous diagnosis of non-muscle invasive bladder cancer.

An analysis showed that glycemic index – but not glycemic load or total carbohydrate intake – significantly increased the risk of developing bladder cancer.

Approximately 18 months after granting Padcev an accelerated approval, the Food and Drug Administration granted a regular approval to the treatment for certain previously treated patients with locally advanced or metastatic urothelial carcinoma.

Agent Orange exposure impacted millions of U.S. military personnel during the Vietnam War. The chemical may have led to bladder cancer diagnoses later in life.

Keytruda plus gemcitabine and higher doses of radiotherapy showed promising efficacy and safety results in patients with muscle-invasive bladder cancer.

Patients who tested positive for the biomarker circulating tumor DNA (ctDNA) had improved disease-free and overall survival after receiving Tecentriq.

The study’s lead author noted that the data support giving patients with advanced bladder cancer chemotherapy to get control of the disease and then maintaining that control with maintenance Bavencio.

Some of the most popular YouTube videos about bladder cancer are of poor quality, spread misinformation and have commercial bias.

A retirement counselor with bladder cancer shares the story of his diagnosis and his thoughts on treatment.

A roundup of some of CURE®’s latest news and updates for patients with bladder cancer in honor of Bladder Cancer Awareness Month this May.

FDA committee members recently voted in favor of upholding Tecentriq’s accelerated approval indication for the first-line treatment of certain adults with locally advanced or metastatic urothelial carcinoma who are ineligible for standard chemotherapy.

Several factors were associated with patients undergoing radical nephrectomy compared with radical nephroureterectomy including Black race, large tumors, advanced tumor stage and high-grade tumors.

Trodelvy has received accelerated approval from the FDA for the treatment of patients with advanced urothelial cancer.

Adjusting the dose of cisplatin, when added to regular doses of Abraxane and gemcitabine, led to similar survival rates when treating patients with advanced/metastatic urothelial carcinoma, which may help to address issues commonly seen with patients who cannot tolerate cisplatin such as renal dysfunction.

If patients were receiving Tecentriq for prior platinum-based treated metastatic urothelial carcinoma, they should discuss next best steps with their health care providers.

To discuss the projected rise in bladder cancer cases in 2021, CURE® spoke with Bladder Cancer Advocacy Network (BCAN) co-founder Diane Zipursky-Quale, who offered some insight on why the numbers continue to rise, and provides some hope in the form of educational programs offered by her organization.

Treatment with Padcev, compared to chemotherapy, continues to show better results in patients with advanced urothelial carcinoma who had previously received certain therapies.

In Episode 2 of the “Bladder Cancer Matters” podcast, host Rick Bangs interviews Dr. Heather Honoré Goltz in Part 2 of a two-part episode.

The Bladder Cancer Advocacy Network's new podcast by, for, and about the bladder cancer community, "Bladder Cancer Matters," has a new episode available.

In the inaugural “Bladder Cancer Matters” podcast, host Rick Bangs interviews Dr. Ashish Kamat about the state of BCG in bladder cancer treatment. Dr. Kamat is a Professor (Tenure) of Urology and Director of Urologic Oncology Fellowship at MD Anderson Cancer Center, and a graduate of the AUA Leadership Program. Dr. Kamat also serves on BCAN’s Scientific Advisory Board.

The Bladder Cancer Advocacy Network (BCAN) announced that it is accepting applications for our 2021 Young Investigator Awards (YIAs).

BCAN is pleased to announce two 2021 Bladder Cancer Research Innovation Awards to support the work of investigators with exceptionally novel and creative projects with great potential to produce breakthroughs in our understanding of the management of bladder cancer.

The Bladder Cancer Advocacy Network’s (BCAN’s) strong financial health and commitment to accountability and transparency have earned it a seventh consecutive 4-star rating from Charity Navigator, America’s largest independent charity evaluator. This award puts BCAN in the top seven percent of all charities.

The Bladder Cancer Advocacy Network (BCAN) is pleased that the U.S. Senate voted overwhelmingly to approve the National Defense Authorization Act (NDAA) which contains a critical provision that will help veterans who were exposed to Agent Orange and later developed bladder cancer.

Predicting risk for recurrence and progression in patients with nonmuscle-invasive bladder cancer may help when discussing management options with clinicians.

Patients with advanced or metastatic bladder cancer, after responding to initial treatment with chemotherapy, may preserve their health improvements by starting immunotherapy immediately.